Wall Street analysts forecast that AstraZeneca plc (NYSE:AZN) will announce $0.47 earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for AstraZeneca’s earnings, with the lowest EPS estimate coming in at $0.43 and the highest estimate coming in at $0.49. AstraZeneca posted earnings per share of $0.37 during the same quarter last year, which would indicate a positive year-over-year growth rate of 27%. The company is expected to issue its next quarterly earnings report before the market opens on Thursday, July 30th.
On average, analysts expect that AstraZeneca will report full year earnings of $2.03 per share for the current fiscal year, with EPS estimates ranging from $1.94 to $2.08. For the next fiscal year, analysts expect that the firm will post earnings of $2.61 per share, with EPS estimates ranging from $2.38 to $3.01. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for AstraZeneca.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.06. AstraZeneca had a return on equity of 33.97% and a net margin of 5.94%. The firm had revenue of $6.35 billion for the quarter, compared to analysts’ expectations of $5.95 billion. During the same period in the prior year, the business posted $0.89 earnings per share. The business’s revenue was up 16.3% compared to the same quarter last year.
A number of brokerages have weighed in on AZN. Morgan Stanley reiterated an “equal weight” rating on shares of AstraZeneca in a research report on Wednesday, May 6th. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a research report on Monday, April 27th. Zacks Investment Research upgraded AstraZeneca from a “hold” rating to a “buy” rating and set a $54.00 target price on the stock in a report on Monday, June 15th. Cowen increased their target price on AstraZeneca from $55.00 to $60.00 in a report on Wednesday, June 10th. Finally, SVB Leerink increased their target price on AstraZeneca from $60.00 to $65.00 and gave the stock an “outperform” rating in a report on Friday, May 29th. Four analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $59.75.
Large investors have recently added to or reduced their stakes in the stock. Verus Capital Partners LLC acquired a new position in AstraZeneca in the 4th quarter valued at $27,000. Patriot Financial Group Insurance Agency LLC lifted its stake in shares of AstraZeneca by 223.8% in the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 557 shares of the company’s stock valued at $25,000 after purchasing an additional 385 shares during the period. OmniStar Financial Group Inc. acquired a new position in shares of AstraZeneca in the 1st quarter valued at about $26,000. Golden State Wealth Management LLC acquired a new position in shares of AstraZeneca in the 1st quarter valued at about $31,000. Finally, Americana Partners LLC acquired a new position in AstraZeneca during the 4th quarter worth approximately $37,000. 16.84% of the stock is owned by institutional investors and hedge funds.
NYSE:AZN traded up $0.21 during trading hours on Tuesday, reaching $52.91. The company had a trading volume of 4,526,100 shares, compared to its average volume of 4,623,390. The stock has a 50-day moving average of $53.55 and a two-hundred day moving average of $49.38. AstraZeneca has a one year low of $36.15 and a one year high of $57.44. The firm has a market capitalization of $138.80 billion, a PE ratio of 89.68, a PEG ratio of 1.57 and a beta of 0.57. The company has a quick ratio of 0.57, a current ratio of 0.75 and a debt-to-equity ratio of 1.32.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: How can investors benefit from after-hours trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.